{"id":15797,"date":"2022-09-05T09:22:05","date_gmt":"2022-09-05T08:22:05","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&#038;p=15797"},"modified":"2022-09-05T09:22:05","modified_gmt":"2022-09-05T08:22:05","slug":"michael-gordon-iceid-2022-oral-sabizabulin-reduces-mortality-in-hospitalized-patients-with-covid-19-at-high-risk-for-acute-respiratory-distress-syndrome","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/covid-19\/conference-hub\/michael-gordon-iceid-2022-oral-sabizabulin-reduces-mortality-in-hospitalized-patients-with-covid-19-at-high-risk-for-acute-respiratory-distress-syndrome\/","title":{"rendered":"Michael Gordon, ICEID 2022: Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome"},"content":{"rendered":"<p><span style=\"font-weight: 400\">Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. <\/span>The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY interview with <b>Dr <\/b><b>Michael Gordon<\/b><span style=\"font-weight: 400\"> (<\/span><span style=\"font-weight: 400\">HonorHealth Research Institute).\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">\u2018<\/span><a href=\"https:\/\/www.iceid2022.com\/Scientific-Program\/Detailed-Scientific-Agenda\" target=\"_blank\" rel=\"noopener\"><i><span style=\"font-weight: 400\">Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome<\/span><\/i><\/a><span style=\"font-weight: 400\">\u2019 was presented at the annual <a href=\"https:\/\/www.iceid.org\/\" target=\"_blank\" rel=\"noopener\">International Conference on Emerging Infectious Diseases (ICEID)<\/a>, August 7\u201310, 2022.<\/span><\/p>\n<ol>\n<li><span style=\"font-weight: 400\"> What is sabizabulin and what is the rationale for its use in the treatment of COVID-19? (00:21)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> What were the aims, design and eligibility criteria of the VERU-111 clinical trial? (02:05)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> What were the primary and secondary endpoints, and how well were they achieved? (04:38)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> What was the safety profile of sabizabulin? (06:57)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> What were the limitations of the study and what further studies are needed? (08:06)<\/span><\/li>\n<\/ol>\n<p><b>Disclosures<\/b><span style=\"font-weight: 400\">: Michael Gordon is a <\/span><span style=\"font-weight: 400\">consultant for OnQuality, Viracta, Qualigen, Leaderboard and MorphicTx; he receives grant\/research support from Veru, FujiFilm, ATEA, Beigene, Incyte, Kinevant, Redhill and Syndax; he is on the Advisory Board for Pfizer.<\/span><\/p>\n<p><b>Support<\/b><span style=\"font-weight: 400\">: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.\u00a0<\/span><\/p>\n<p><b><i>Filmed as a highlight of ICEID 2022<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY interview with Dr Michael Gordon (HonorHealth Research Institute).\u00a0 \u2018Oral sabizabulin reduces mortality in hospitalized patients [&hellip;]<\/p>\n","protected":false},"featured_media":15798,"template":"","class_list":["post-15797","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-covid-19","video_categories-iceid-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/15797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":2,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/15797\/revisions"}],"predecessor-version":[{"id":15800,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/15797\/revisions\/15800"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media\/15798"}],"wp:attachment":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media?parent=15797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}